表柔比星联合紫衫醇治疗三阴性乳腺癌的临床观察

Clinical Observation of Epirubicin Combined with Paclitaxel for Triple Negative Breast Cancer

目的探讨表柔比星联合紫衫醇治疗三阴性乳腺癌的临床效果。方法 85例三阴性乳腺癌患者分为对照组(39例)和观察组(46例),对照组以环磷酰胺联合表阿霉素化疗,观察组患者进行表柔比星联合紫杉醇的新辅助化疗法,治疗结束后对两组有效率、治疗前后肿瘤直径大小、叉头框蛋白A1(FOXAl)和乳腺癌易感基因(BRCAl)蛋白表达水平以及术后不良反应发生情况进行统计。结果治疗后,对照组和观察组的总有效率分别为64.1%和84.9%,观察组有效率显著高于对照组(P<0.05);在治疗后,两肿瘤直径大小、癌细胞中FOXAl和BRCAI蛋白水平较治疗前均显著下降(P<0.05),且观察组显著低于对照组(P<0.05);观察组和治疗组治疗后不良反应发生率分别为13.0%和17.9%,经比较,无显著性差异(P>0.05)。结论表柔比星联合紫杉醇对三阴性乳腺癌的临床治疗效果显著,且对于肿瘤的缩小,FOXAl、BRCAl水平降低等有显著的效果。

Objective To investigate the clinical effect of epirubicin combined with paclitaxel for triple negative breast cancer.Methods 85 patients with triple negative breast cancer were divided into the control group （39 cases） and the observa-tion group （46 cases）,The control group received cyclophosphamide joined table doxorubicin chemotherapy ,the observation group received epirubicin combination paclitaxel neoadjuvant chemotherapy method ,Efficacy,tumor diameter size,FOXAl and BRCAl protein expression levels and postoperative adverse reactions of the 2 groups before and after treatment were analyzed .Results After treatment,total effective rates of the control group and the observation group were 64.1%and 84.9%,respectively,effective rate of the observation group was significantly higher than the control group （P〈0.05）;After treatment,tumor size,diameter of cancer cells,BRCAI and FOXAl protein levels significantly decreased （P〈0.05）,and the observation group was significantly lower than the control group （P〈0.05）;after treatment,adverse reaction rates the observation group and the control group were 13.0%and 17.9%,respectively,there had no significant difference （P〉0.05）.Conclusion Epirubicin combined with pacli-taxel for triple negative breast cancer is effective ,and have a significant effect in decreasing tumors and FOXAl ,BRCAl levels.